siRNA Delivery Technology for Cancer Therapy: Promise and Challenges

  • Fateme Karimi Dermani Department of Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Farid Azizi Jalilian Department of Medical Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Hossein Hossienkhani Innovation Center for Advanced Technology, Matrix, Inc., New York, NY 10029, USA.
  • Razieh Ezati Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
  • Razieh Amini Mail Department of Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. AND Molecular Medicine Research Center, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Small interfering RNA (siRNA), Cancer therapy, Delivery systems, Nanoparticles


Small interfering RNAs (siRNA) technology has shown great promise as a new class of therapeutic interventions for the treatment of cancer and other diseases. It is a remarkable endogenous pathway that can regulate sequence-specific gene silencing. Despite the excitement about possible applications of this biological process for sequence-specific gene regulation, the major limitations against the use of siRNA-based therapeutics are their rapid degradation by serum nuclease, poor cellular uptake, and rapid renal clearance following systemic delivery, off-target effects and the induction of immune responses. Many researchers have tried to overcome these limitations by developing nuclease-resistant chemically-modified siRNAs and a variety of synthetic and natural biodegradable lipids and polymers to enhance the efficacy and safety profiles of siRNA delivery. Ideal siRNA-based delivery systems for cancer therapy must be clinically suitable, safe and effective. In this review, we introduce the greatest challenges in achieving efficient RNAi delivery and discuss design criteria and various delivery strategies for cancer therapy, including chemical modifications, lipid-based nano-vectors, polymer-mediated delivery systems, conjugate delivery systems, and others.


Ozcan, G., et al., Preclinical and clinical development of siRNA-based therapeutics. Advanced drug delivery reviews, 2015. 87: p. 108-119.

Fire, A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. nature, 1998. 391(6669): p. 806-811.

Elbashir, S.M., et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. nature, 2001. 411(6836): p. 494-498.

Meister, G. and T. Tuschl, Mechanisms of gene silencing by double-stranded RNA. Nature, 2004. 431(7006): p. 343-349.

Siomi, H. and M.C. Siomi, On the road to reading the RNA-interference code. Nature, 2009. 457(7228): p. 396-404.

de Fougerolles, A., et al., Interfering with disease: a progress report on siRNA-based therapeutics. Nature reviews Drug discovery, 2007. 6(6): p. 443-453.

Kim, D.H. and J.J. Rossi, Strategies for silencing human disease using RNA interference. Nature Reviews Genetics, 2007. 8(3): p. 173-184.

Pecot, C.V., et al., RNA interference in the clinic: challenges and future directions. Nature Reviews Cancer, 2011. 11(1): p. 59-67.

Yiu, S.-M., et al., Filtering of ineffective siRNAs and improved siRNA design tool. Bioinformatics, 2005. 21(2): p. 144-151.

Naito, Y. and K. Ui-Tei, Designing functional siRNA with reduced off-target effects. siRNA Design: Methods and Protocols, 2013: p. 57-68.

Chalk, A.M., C. Wahlestedt, and E.L. Sonnhammer, Improved and automated prediction of effective siRNA. Biochemical and biophysical research communications, 2004. 319(1): p. 264-274.

Xu, C.-f. and J. Wang, Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences, 2015. 10(1): p. 1-12.

Juliano, R., et al., Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic acids research, 2008. 36(12): p. 4158-4171.

Bartlett, D.W. and M.E. Davis, Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing. Biotechnology and bioengineering, 2007. 97(4): p. 909-921.

Volkov, A.A., et al., Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides, 2009. 19(2): p. 191-202.

Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage activation. Nature reviews immunology, 2008. 8(12): p. 958-969.

Behlke, M.A., Chemical modification of siRNAs for in vivo use. Oligonucleotides, 2008. 18(4): p. 305-320.

Braasch, D.A., et al., Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorganic & medicinal chemistry letters, 2004. 14(5): p. 1139-1143.

Soutschek, J., et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004. 432(7014): p. 173-178.

Ozpolat, B., A. Sood, and G. Lopez‐Berestein, Nanomedicine based approaches for the delivery of siRNA in cancer. Journal of internal medicine, 2010. 267(1): p. 44-53.

Sioud, M., Deciphering the code of innate immunity recognition of siRNAs. siRNA and miRNA Gene Silencing: From Bench to Bedside, 2009: p. 1-19.

Judge, A.D., et al., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature biotechnology, 2005. 23(4): p. 457-462.

Hornung, V., et al., Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature medicine, 2005. 11(3): p. 263-270.

Bitko, V., et al., Inhibition of respiratory viruses by nasally administered siRNA. Nature medicine, 2005. 11(1): p. 50-55.

Thomas, M., et al., Non-viral siRNA delivery to the lung. Advanced drug delivery reviews, 2007. 59(2): p. 124-133.

Pardridge, W.M., shRNA and siRNA delivery to the brain. Advanced drug delivery reviews, 2007. 59(2): p. 141-152.

Fattal, E. and A. Bochot, Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Advanced drug delivery reviews, 2006. 58(11): p. 1203-1223.

Whitehead, K.A., R. Langer, and D.G. Anderson, Knocking down barriers: advances in siRNA delivery. Nature reviews Drug discovery, 2009. 8(2): p. 129-138.

Castanotto, D. and J.J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics. Nature, 2009. 457(7228): p. 426-433.

Barquinero, J., H. Eixarch, and M. Perez-Melgosa, Retroviral vectors: new applications for an old tool. Gene therapy, 2004. 11: p. S3-S9.

Wang, J., et al., Delivery of siRNA therapeutics: barriers and carriers. The AAPS journal, 2010. 12(4): p. 492-503.

Lewis, D.L. and J.A. Wolff, Systemic siRNA delivery via hydrodynamic intravascular injection. Advanced drug delivery reviews, 2007. 59(2): p. 115-123.

Unnamalai, N., B.G. Kang, and W.S. Lee, Cationic oligopeptide‐mediated delivery of dsRNA for post‐transcriptional gene silencing in plant cells. FEBS letters, 2004. 566(1-3): p. 307-310.

Durzyńska, J., et al., Viral and other cell-penetrating peptides as vectors of therapeutic agents in medicine. Journal of Pharmacology and Experimental Therapeutics, 2015. 354(1): p. 32-42.

Margus, H., K. Padari, and M. Pooga, Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Molecular Therapy, 2012. 20(3): p. 525-533.

Akhtar, S. and I.F. Benter, Nonviral delivery of synthetic siRNAs in vivo. The Journal of clinical investigation, 2007. 117(12): p. 3623-3632.

Akhtar, S., et al., The delivery of antisense therapeutics. Advanced drug delivery reviews, 2000. 44(1): p. 3-21.

Kawakami, S. and M. Hashida, Targeted delivery systems of small interfering RNA by systemic administration. Drug metabolism and pharmacokinetics, 2007. 22(3): p. 142-151.

Agarwal, A., R. Unfer, and S.K. Mallapragada, Novel cationic pentablock copolymers as non-viral vectors for gene therapy. Journal of controlled release, 2005. 103(1): p. 245-258.

Jackson, A.L. and P.S. Linsley, Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature reviews Drug discovery, 2010. 9(1): p. 57-67.

De Martimprey, H., et al., Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. European journal of pharmaceutics and biopharmaceutics, 2009. 71(3): p. 490-504.

Ramamoorth, M. and A. Narvekar, Non viral vectors in gene therapy-an overview. Journal of clinical and diagnostic research: JCDR, 2015. 9(1): p. GE01.

Biswas, S. and V.P. Torchilin, Dendrimers for siRNA delivery. Pharmaceuticals, 2013. 6(2): p. 161-183.

McCarroll, J. and M. Kavallaris, Nanoparticle delivery of siRNA as a novel therapeutic for human disease. Nucleus, 2012. 7: p. m7G.

Lee, J.-H., et al., Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicology letters, 2009. 190(2): p. 202-207.

Patil, M.L., et al., Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules, 2009. 10(2): p. 258-266.

Jevprasesphant, R., et al., The influence of surface modification on the cytotoxicity of PAMAM dendrimers. International journal of pharmaceutics, 2003. 252(1): p. 263-266.

Patil, M.L., et al., Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjugate chemistry, 2008. 19(7): p. 1396-1403.

Lee, J.-M., T.-J. Yoon, and Y.-S. Cho, Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed research international, 2013. 2013.

Katas, H. and H.O. Alpar, Development and characterisation of chitosan nanoparticles for siRNA delivery. Journal of controlled release, 2006. 115(2): p. 216-225.

Mao, S., W. Sun, and T. Kissel, Chitosan-based formulations for delivery of DNA and siRNA. Advanced drug delivery reviews, 2010. 62(1): p. 12-27.

Baldrick, P., The safety of chitosan as a pharmaceutical excipient. Regulatory Toxicology and Pharmacology, 2010. 56(3): p. 290-299.

Kean, T. and M. Thanou, Biodegradation, biodistribution and toxicity of chitosan. Advanced drug delivery reviews, 2010. 62(1): p. 3-11.

Raemdonck, K., et al., Polysaccharide-based nucleic acid nanoformulations. Advanced drug delivery reviews, 2013. 65(9): p. 1123-1147.

Riva, R., et al., Chitosan and chitosan derivatives in drug delivery and tissue engineering, in Chitosan for biomaterials II. 2011, Springer. p. 19-44.

Ragelle, H., et al., Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. Journal of Controlled Release, 2014. 176: p. 54-63.

Pathak, A., S. Patnaik, and K.C. Gupta, Recent trends in non‐viral vector‐mediated gene delivery. Biotechnology journal, 2009. 4(11): p. 1559-1572.

Xu, Q., C.-H. Wang, and D. Wayne Pack, Polymeric carriers for gene delivery: chitosan and poly (amidoamine) dendrimers. Current pharmaceutical design, 2010. 16(21): p. 2350-2368.

Tucker, G.C., Integrins: molecular targets in cancer therapy. Current oncology reports, 2006. 8(2): p. 96-103.

Danhier, F., A.L. Breton, and V.r. Préat, RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Molecular pharmaceutics, 2012. 9(11): p. 2961-2973.

Morille, M., et al., Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 2008. 29(24): p. 3477-3496.

Templeton, N.S., Gene and cell therapy: therapeutic mechanisms and strategies. 2015: CRC Press.

Du, J., et al., Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. International journal of molecular sciences, 2012. 13(1): p. 516-533.

Howard, K.A., Delivery of RNA interference therapeutics using polycation-based nanoparticles. Advanced drug delivery reviews, 2009. 61(9): p. 710-720.

Scholz, C. and E. Wagner, Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. Journal of controlled release, 2012. 161(2): p. 554-565.

Li, J., et al., Copolymer of poly (ethylene glycol) and poly (L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery. Nanoscale, 2014. 6(3): p. 1732-1740.

Guo, J., et al., Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnology advances, 2011. 29(4): p. 402-417.

Cartiera, M.S., et al., The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials, 2009. 30(14): p. 2790-2798.

Katas, H., E. Cevher, and H.O. Alpar, Preparation of polyethyleneimine incorporated poly (d, l-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. International journal of pharmaceutics, 2009. 369(1): p. 144-154.

Bruno, K., Using drug-excipient interactions for siRNA delivery. Advanced drug delivery reviews, 2011. 63(13): p. 1210-1226.

Lobovkina, T., et al., In vivo sustained release of siRNA from solid lipid nanoparticles. ACS nano, 2011. 5(12): p. 9977-9983.

Tahara, K., et al., Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. International journal of pharmaceutics, 2008. 354(1): p. 210-216.

Díez, S., G. Navarro, and C.T. de ILarduya, In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. The journal of gene medicine, 2009. 11(1): p. 38-45.

Te Boekhorst, B.C., et al., MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. Journal of controlled release, 2012. 161(3): p. 772-780.

Jensen, D.K., et al., Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of controlled release, 2012. 157(1): p. 141-148.

Oh, Y.-K. and T.G. Park, siRNA delivery systems for cancer treatment. Advanced drug delivery reviews, 2009. 61(10): p. 850-862.

Morrissey, D.V., et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature biotechnology, 2005. 23(8): p. 1002-1007.

Zhang, J., X. Li, and L. Huang, Non-viral nanocarriers for siRNA delivery in breast cancer. Journal of Controlled Release, 2014. 190: p. 440-450.

Gao, Y., X.-L. Liu, and X.-R. Li, Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine, 2011. 6(1): p. 1017-1025.

Ozpolat, B., A.K. Sood, and G. Lopez-Berestein, Liposomal siRNA nanocarriers for cancer therapy. Advanced drug delivery reviews, 2014. 66: p. 110-116.

Deng, Y., et al., Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene, 2014. 538(2): p. 217-227.

Guo, P., et al., Engineering RNA for targeted siRNA delivery and medical application. Advanced drug delivery reviews, 2010. 62(6): p. 650-666.

Kapoor, M. and D.J. Burgess, Efficient and safe delivery of siRNA using anionic lipids: formulation optimization studies. International journal of pharmaceutics, 2012. 432(1): p. 80-90.

Burnett, J.C. and J.J. Rossi, RNA-based therapeutics: current progress and future prospects. Chemistry & biology, 2012. 19(1): p. 60-71.

Petros, R.A. and J.M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications. Nature reviews Drug discovery, 2010. 9(8): p. 615-627.

Khvalevsky, E.Z., et al., Mutant KRAS is a druggable target for pancreatic cancer. Proceedings of the National Academy of Sciences, 2013. 110(51): p. 20723-20728.

Davis, M.E., et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010. 464(7291): p. 1067-1070.

Davis, M.E., The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Molecular pharmaceutics, 2009. 6(3): p. 659-668.

Zuckerman, J.E., et al., Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proceedings of the National Academy of Sciences, 2014. 111(31): p. 11449-11454.

Tabernero, J., et al., First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer discovery, 2013.

Strumberg, D., et al., Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. International Journal of Clinical Pharmacologyand Therapeutics, 2012. 50(1): p. 76.

Schultheis, B., et al., First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. Journal of Clinical Oncology, 2014. 32(36): p. 4141-4148.

Landen, C.N., et al., Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer research, 2005. 65(15): p. 6910-6918.

Ewe, A., et al., Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo. Nanomedicine: Nanotechnology, Biology and Medicine, 2017. 13(1): p. 209-218.

How to Cite
Karimi Dermani F, Azizi Jalilian F, Hossienkhani H, Ezati R, Amini R. siRNA Delivery Technology for Cancer Therapy: Promise and Challenges. Acta Med Iran. 57(2):83-93.
Review Article(s)